Literature DB >> 10560679

Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.

N R Poulter, C L Chang, T M Farley, O Meirik.   

Abstract

Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10560679     DOI： 10.1016/s0140-6736(99)03132-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  6 in total

1.  Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study.

Authors:  Michel K Barsoum; John A Heit; Aneel A Ashrani; Cynthia L Leibson; Tanya M Petterson; Kent R Bailey
Journal:  Thromb Res       Date:  2010-09-15       Impact factor: 3.944

Review 2.  Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS.

Authors:  Lisa R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2021-04-30       Impact factor: 4.592

3.  Obesity hypoventilation syndrome.

Authors:  Laila Al Dabal; Ahmed S Bahammam
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

4.  Obesity Hypoventilation Syndrome and Anesthesia.

Authors:  Edmond H L Chau; Babak Mokhlesi; Frances Chung
Journal:  Sleep Med Clin       Date:  2012-12-14

Review 5.  Assessment and management of patients with obesity hypoventilation syndrome.

Authors:  Babak Mokhlesi; Meir H Kryger; Ronald R Grunstein
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

Review 6.  Sex matters: Practice 5P's when treating young women with venous thromboembolism.

Authors:  Ingrid M Bistervels; Luuk J J Scheres; Eva N Hamulyák; Saskia Middeldorp
Journal:  J Thromb Haemost       Date:  2019-07-23       Impact factor: 5.824
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.